구독하기
연구 모델
서비스
전임상 효능 평가
Resource
huHSC-NKG Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huHSC-NKG Mouse
제품명
huHSC-NKG Mouse
제품 ID
C001328
품종 계통
huHSC-NOD.Cg-PrkdcscidIl2rgem1cya/Cya
Backgroud
NKG
상태
이 마우스 계통을 논문에서 사용할 경우, “huHSC-NKG Mouse (카탈로그 번호 C001328)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Immunodeficient Mice
Humanized Immune System Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Immunodeficient Mice
Humanized Immune System Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자명
유전자 별칭
gc, p64, [g]c, CD132, gamma(c)
NCBI ID
염색체
Chr X
MGI ID
--
Datasheet
품종 계통 설명
NKG mice (catalog number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX).
huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute a variety of immune cells. Furthermore, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be lengthy.
변형 전략
Female NKG mice aged 4-5 weeks were selected to inject CD34+ hematopoietic stem cells (HSCs) through the tail vein after irradiation, and the reconstitution period was 12-16 weeks.
응용 분야
Research on the immune system and tumor immunity;
Research on hematopoietic development and blood diseases;
Research on infectious diseases such as HIV and AIDS;
Research on tumor transplantation and anti-tumor drug efficacy.
검증 데이터
1. NKG mice (Adult) for human CD34+ HSC immune system reconstruction research
（1）Survival curve
The huHSC-NKG adult mice were free of graft-versus-host disease (GvHD) and maintained a high survival rate of over 70% after 150 days post-engraftment.
Figure 1. The survival curve of huHSC-NKG adult mice.
（2）Growth curve
The huHSC-NKG adult mice maintained normal weight gain after the transplantation of huHSC.
Figure 2. The growth curve of huHSC-NKG adult mice.
（3）Proportion of human leukocytes
The percentage of human leukocytes gradually increased, and the average percentage of human CD45+ cells reached more than 60%.
Figure 3. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG adult mice.
（4）Proportions of human T cells and B cells
The reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 16. The proportion of B cells was higher at the early stage, reaching 80%, and decreased to 15% at week 24.
Figure 4. Proportions of human T cells and B cells in huHSC-NKG adult mice.
（5）Proportions of human NK cells and monocytes
The proportions of NK cells and monocytes during immune system reconstitution were low. The average proportion of NK cells maintained at about 2% overall and the proportion of monocytes at week 16 was about 2%.
Figure 5. Proportions of human NK cells and monocytes in huHSC-NKG adult mice.
2. NKG mice (Newborn) for human CD34+ HSC immune system reconstruction research
（1）Survival curve
The huHSC-NKG newborn mice were free of graft-versus-host disease (GvHD). The survival rate of huHSC-NKG newborn mice maintained more than 90% before 100 days post engraftment and the survival rate still maintained more than 80% nearly 150 days post engraftment, which was higher than that of the adult model.
Figure 6. The survival curve of huHSC-NKG newborn mice.
（2）Growth curve
The huHSC-NKG newborn mice maintained normal weight gain after the transplantation of huHSC.
Figure 7. The growth curve of huHSC-NKG newborn mice.
（3）Proportion of human leukocytes
The percentage of human leukocytes gradually increased. The average percentage of human CD45+ leukocytes reached more than 40% after 8 weeks post engraftment and subsequently increased and maintained at about 60%.
Figure 8. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG newborn mice.
（4）Proportions of human T cells and B cells
Similar to the adult model, the reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 14. The proportion of B cells was higher than 80% at the early stage and decreased continuously, dropping to 40% at week 20.
Figure 9. Proportions of human T cells and B cells in huHSC-NKG newborn mice.
（5）Proportions of human NK cells and monocytes
The proportions of NK cells and monocytes were higher in this newborn model than that in the adult model. The average percentage of NK cells was more than 10% in the early stage and maintained at about 5% in the later stage. The average percentage of monocytes was higher than 5%. Therefore, the newborn model is more suitable for studies related to myeloid cell targets.
Figure 10. Proportions of human NK cells and monocytes in huHSC-NKG newborn mice.
관련 자료
1:1 상담
문의 사항이나 도움이 필요하신가요? <br> 아래 양식을 작성해 주시면 Cyagen 팀이 1~2 영업일 이내에 답변드리겠습니다.
관련 제품
모든 관련 제품리소스
출판물
nano today
2025-05-31
Temporal responsive vesicle-INFγ aptamer-PEI/HA system targeted activation of B-CD4T-Tfh-CD8T cells cascade inhibits TNBC progression
자세히 보기
Nano Today
2025-05-31
Temporal responsive vesicle-INFγ aptamer-PEI/HA system targeted activation of B-CD4T-Tfh-CD8T cells cascade inhibits TNBC progression
자세히 보기
Translational Oncology
2025-01-26
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression
자세히 보기
Translational Oncology
2025-01-27
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression
자세히 보기
Items: 1 to 4 of 4
1
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.